A Phase 1B Dose-escalation Study of TRC105 in Combination With Axitinib in Patients With Advanced Renal Cell Carcinoma

A Phase 1B Dose-escalation Study of TRC105 in Combination With Axitinib in Patients With Advanced Renal Cell Carcinoma

Sponsors and Collaborators
Tracon Pharmaceuticals Inc.

Contact
Bonne Adams
badams@traconpharma.com

Manoj Jivani
mjivani@traconpharma.com

ClinicalTrials.gov Identifier
NCT01806064

Loading links....
You must be a registered member of Renal and Urology News to post a comment.

Sign Up for Free e-newsletters